Spirulina and Platelet Aggregation

Platelet Activation: A Self-Amplifying Loop

Platelet activation proceeds through GP1b-vWF tethering, GP6-collagen firm adhesion, and αIIbβ3 integrin activation enabling fibrinogen-mediated aggregation. Activation is amplified by autocrine release of thromboxane A2 (TxA2), ADP, and serotonin from dense granules. This positive feedback enables rapid clot formation but, when dysregulated, drives arterial thrombosis underlying myocardial infarction and stroke.

COX-1 and Thromboxane A2

Platelet cyclooxygenase-1 (COX-1) generates TxA2 from arachidonic acid via the prostaglandin H2 intermediate. TxA2 binds platelet TP receptors, triggering Gαq-PLCβ signaling, calcium mobilization, and shape change. Aspirin's antiplatelet efficacy comes from irreversible COX-1 acetylation. Phycocyanin reversibly inhibits COX-1 with IC50 in the low micromolar range, reducing TxA2 production by 20–35% at tissue-relevant concentrations.

P2Y12 and ADP-Mediated Amplification

Released ADP binds platelet P2Y12 (Gi-coupled), suppressing cAMP and amplifying integrin activation. Clopidogrel and ticagrelor target P2Y12 clinically. Spirulina modulates ADP signaling indirectly via reduced dense granule release: phycocyanin stabilizes platelet membranes against ROS-induced exocytosis, with 15–25% reduction in platelet ATP/ADP release in oxidative-stressed models.

GLA-Driven Eicosanoid Shift

Spirulina is a notable plant source of gamma-linolenic acid (GLA, 18:3 n-6) at ~1–1.2% by dry weight. GLA elongates to dihomo-gamma-linolenic acid (DGLA, 20:3 n-6), substrate for prostaglandin E1 (PGE1) — a vasodilatory and anti-aggregatory prostanoid. PGE1 raises platelet cAMP via Gs-coupled EP4 receptors, opposing P2Y12-mediated cAMP suppression. Shifting platelet phospholipid composition toward DGLA tilts the eicosanoid balance.

Nitric Oxide and Endothelial Antiplatelet Signaling

Endothelial NO (from eNOS) elevates platelet cGMP via soluble guanylate cyclase, inhibiting activation. Spirulina's effect on endothelial function — phycocyanin preserves eNOS dimerization by reducing tetrahydrobiopterin (BH4) oxidation — enhances this endothelial antiplatelet tone. eNOS coupling improvement: 20–35% in cardiovascular risk populations.

Conclusion

Spirulina provides a multi-target antiplatelet profile: 20–35% TxA2 reduction (COX-1 inhibition), 15–25% reduced dense granule release (oxidative protection), shifted eicosanoid balance toward DGLA/PGE1 (GLA provision), and enhanced endothelial NO bioavailability (eNOS coupling). Unlike aspirin or P2Y12 inhibitors, these effects are reversible and titratable, with no clinical bleeding-risk signal in controlled studies up to 8 g/day. The multi-mechanism profile is relevant for metabolic syndrome and diabetes — populations with platelet hyperreactivity but also elevated bleeding risk on conventional antiplatelet therapy.